Login to Your Account



Probiodrug Gets €36M for Novel Alzheimer's Program

By Cormac Sheridan


Tuesday, November 3, 2009

No Abstract

 

BioWorld Today Correspondent

In what could well be Europe's largest venture capital investment in biotechnology this year, Probiodrug AG took in more than €36 million (US$53.4 million) in a Series B round to fund a new class of Alzheimer's disease drugs, based on inhibiting glutaminyl cyclase (QC). The company also will allocate part of the proceeds to developing compounds acting on the same target for treating inflammatory indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription